Literature DB >> 6212596

Cefoperazone disk diffusion susceptibility test: confirmation of the tentative interpretive criteria, Pseudomonas aeruginosa cross-resistance, and determination of quality control performance limits.

R N Jones, T L Gavan, A L Barry, C Thornsberry, D L Gibbs.   

Abstract

Cefoperazone disk diffusion test and minimum inhibitory concentration comparison studies were performed on 421 recent bacterial isolates, using 30- and 75-micrograms commercially prepared disks. Acceptable correlation coefficients (-0.82 to -0.86) and very major (false-susceptible) interpretive error rates (less than 1%) were obtained with both disk concentrations. The interpretive criteria for both disks were identical. Using the preferred 75-micrograms disk, the Thornsberry et al. criteria (J. Clin. Microbiol. 15:769-776, 1982) of greater than or equal to 18 mm = susceptible (less than or equal to 32 micrograms/ml) and less than or equal to 14 mm = resistant (greater than 64 micrograms/ml) resulted in only 5.5% of strains having indeterminate-range zone diameters; the 30-micrograms disk had 6.9% of strains with indeterminate zone diameters. The 75-micrograms disk, excluding the testing of enterococci, minimized the very major and other interpretive errors to less than 5%. Larger zone diameters will contribute few technical problems with either disk concentration. Data from 1,320 zone diameters submitted for each quality control strain indicated no significant (P greater than 0.05) difference between disks made by the three major manufacturers, and consistent results were obtained within each laboratory with numerous lots of Mueller-Hinton agar (except for one manufacturer). Individual daily test and accuracy quality control ranges were calculated from clinical investigator laboratory data at 16 hospitals based on mean zone sizes and from an additional 8 laboratories with both mean and median calculations. The quality control data were nearly identical, and ranges calculated by the two methods were very similar. Susceptibility tests of Pseudomonas aeruginosa indicate that the cefoperazone disk or minimum inhibitory concentration test would accurately predict P. aeruginosa susceptibility test results for other pseudomonas-active cephalosporins (cefsulodin and ceftazidime), thus producing no very major interpretive errors.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6212596      PMCID: PMC272189          DOI: 10.1128/jcm.15.5.777-786.1982

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  29 in total

1.  Comparative pharmacokinetics of cefoperazone and cefotaxime.

Authors:  H Lode; B Kemmerich; P Koeppe; D Belmega; H Jendroschek
Journal:  Clin Ther       Date:  1980       Impact factor: 3.393

2.  Cefoperazone: absorption, excretion, distribution, and metabolism.

Authors:  K Shimizu
Journal:  Clin Ther       Date:  1980       Impact factor: 3.393

3.  Microbiological studies on cefoperazone.

Authors:  F H Kayser
Journal:  Clin Ther       Date:  1980       Impact factor: 3.393

4.  Cefoperazone: pharmacokinetics in humans with normal and impaired renal function and pharmacokinetics in rats.

Authors:  L Balant; P Dayer; M Rudhardt; A F Allaz; J Fabre
Journal:  Clin Ther       Date:  1980       Impact factor: 3.393

5.  Single-dose pharmacokinetics of cefoperazone following intravenous administration.

Authors:  W A Craig
Journal:  Clin Ther       Date:  1980       Impact factor: 3.393

6.  Antibacterial activity of ceftizoxime (FK 749), a new cephalosporin, against cephalosporin-resistant bacteria, and its stability to beta-lactamase.

Authors:  H Kojo; M Nishida; S Goto; S Kuwahara
Journal:  Antimicrob Agents Chemother       Date:  1979-11       Impact factor: 5.191

7.  Cefoperazone (T-1551), a new semisynthetic cephalosporin: comparison with cephalothin and gentamicin.

Authors:  R N Jones; P C Fuchs; A L Barry; T L Gavan; H M Sommers; E H Gerlach
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

8.  Ceftizoxime (FK 749), a new parenteral cephalosporin: in vitro and in vivo antibacterial activities.

Authors:  T Kamimura; Y Matsumoto; N Okada; Y Mine; M Nishida; S Goto; S Kuwahara
Journal:  Antimicrob Agents Chemother       Date:  1979-11       Impact factor: 5.191

9.  Affinities of penicillins and cephalosporins for the penicillin-binding proteins of Escherichia coli K-12 and their antibacterial activity.

Authors:  N A Curtis; D Orr; G W Ross; M G Boulton
Journal:  Antimicrob Agents Chemother       Date:  1979-11       Impact factor: 5.191

10.  In vitro antibacterial activity and susceptibility of cefsulodin, an antipseudomonal cephalosporin, to beta-lactamases.

Authors:  A King; K Shannon; I Phillips
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

View more
  5 in total

1.  Error rates in cefoperazone and cefoperazone-sulbactam disk tests with Enterobacteriaceae and Pseudomonas aeruginosa.

Authors:  D J Hardy; A L Barry; P C Fuchs; E H Gerlach; J C McLaughlin; M A Pfaller
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-10       Impact factor: 3.267

2.  Criteria for disk susceptibility tests and quality control guidelines for the cefoperazone-sulbactam combination.

Authors:  A L Barry; R N Jones
Journal:  J Clin Microbiol       Date:  1988-01       Impact factor: 5.948

3.  Tentative interpretive criteria for in vitro antibacterial susceptibility testing with imipenem.

Authors:  D L Shungu; A T Cerami; E Weinberg; T Capizzi; H H Gadebusch
Journal:  J Clin Microbiol       Date:  1986-03       Impact factor: 5.948

4.  Single-strain regression analysis for determination of interpretive breakpoints for cefoperazone disk diffusion susceptibility testing.

Authors:  G Kronvall
Journal:  J Clin Microbiol       Date:  1983-06       Impact factor: 5.948

5.  Disk agar diffusion susceptibility testing with 30-micrograms ceftazidime disks: confirmation of interpretive breakpoints and quality control guidelines.

Authors:  R N Jones; A L Barry; C Thornsberry
Journal:  J Clin Microbiol       Date:  1983-07       Impact factor: 5.948

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.